AbCellera

AbCellera, founded in 2012, is a biotechnology firm headquartered in Vancouver, Canada, that specializes in antibody discovery and development. The company utilizes a proprietary technology platform integrating single-cell screening, machine learning, and high-throughput genomics to identify therapeutic antibodies. By collaborating with pharmaceutical and biotechnology partners, AbCellera accelerates the development of antibody-based medicines targeting oncology, autoimmune diseases, and infectious diseases. Their platform is designed to handle complex protein profiling, enabling the rapid identification of high-quality candidates for clinical development.

Operating with 500-1,000 employees, AbCellera maintains a robust operational footprint focused on innovation in protein profiling and therapeutic identification. The organization leverages its advanced computational and experimental capabilities to streamline the transition from discovery to clinical application. Meet AbCellera's team to learn about the leadership and scientific experts driving these complex R&D initiatives across their research facilities. The company’s focus on high-throughput screening allows for the efficient analysis of large datasets, which is critical for modern drug discovery and the advancement of next-generation therapies.

Publicly traded under the ticker NASDAQ: ABCL, the company demonstrates significant market presence within the biotechnology sector. With annual revenue reaching $66.2M, AbCellera continues to expand its influence through strategic partnerships and high-throughput screening technologies. The firm competes with entities like Zymeworks and Stemcell Technologies, maintaining a competitive edge through its unique integration of data science and biology. Explore financial highlights to review detailed metrics regarding their equity, funding history, and fiscal performance.